Reed Smith partner Stephen McConnell will be speaking on the panel titled, "Class Action Activity Roundup: Addressing The Latest and Greatest in Plaintiffs’ Bar Attacks on OTC Drug Products" on January 24, 2024. His session will include assessing the latest emerging OTC product liability and false advertising litigations and class action activity, addressing the rising trend of consumer advocacy research labs performing their own testing on OTC products that are spawning product recalls and class litigations, discussing navigating the unique challenges inherent to OTC product litigations, and exploring safeguarding your company and brand against the risk of false advertising/deception class actions.

Featured sessions, include:

• A Spotlight on FDA’s newly proposed ACNU Rule and Monograph Reform updates featuring FDA commentary
• A Think tank on the reclassification of Phenylephrine
• PFAS concerns for OTCs
• Cases Studies on recent Rx- to-OTC Switches: Analyzing the legal and regulatory implications of the Opill and Naloxone switches
• Special focus sessions on the Homeopathic Monograph and MoCRA’s impact on the OTC industry
• Advertising drill down on the impact of the FTC’s Health Claims and Influencer Guidances and Green Guides on OTC promotion
• OTC Post Marketing Challenges: Addressing Adverse Events, Product Recalls, Inspection and Investigations

Join us in New York City on January 23-24 to meet and benchmark with present and former FDA and FTC enforcers, NAD representatives, and leading OTC industry stakeholders. Attend and walk away with an enhanced understanding of how to navigate the current OTC legal and regulatory environment.